project id: TCGA-PRAD; case submitter id: TCGA-EJ-7312; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.85; age at index: 58; days to birth: -21292; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1953; age at diagnosis: 21292; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1099.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; days to collection: 832; initial weight: 320.0; oct embedded: true; sample id: 3ea3bcfc-2030-4d0b-b9b2-840a9ad1acaf; sample submitter id: TCGA-EJ-7312-01B; portion id: 5acc7363-b1d3-4de6-add0-2cf408a615da; portion submitter id: TCGA-EJ-7312-01B-21; slide id: 1a8e71d6-708a-4ac7-a502-7d3e98687e25; slide submitter id: TCGA-EJ-7312-01B-02-TSB; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 90.0; section location: TOP;